TY - JOUR
T1 - Somatostatin inhibits pancreatic exocrine secretion via a neural mechanism
AU - Mulvihill, Sean J.
AU - Bunnett, Nigel W.
AU - Goto, Yoshiaki
AU - Debas, Haile T.
N1 - Funding Information:
From the Department of Surgery, University of Cahfirnia San Francisco School of Medicine, San Francisco, CA. Supported by a grantjiom the National Institute ofDiabetes and Digestive and Kidney Diseases (ROl DK40471). Dr Goto was a visiting scientist from the University of Tokushima-Bunri. Tokushima, Japan. Address reprint requests to Sean J. Mulvihill, MD, Department of Surgery, U-122, University of Cahfornia San Francisco School of Medicine, San Francisco, CA 94143-0788. 0 1990 by W.B. Saunders Company. 00260495/90/3909-2038$03.00/O
PY - 1990/9
Y1 - 1990/9
N2 - The mechanism of inhibition of pancreatic exocrine secretion by somatostatin is unknown. We hypothesized that somatostatin acts indirectly, via intrinsic pancreatic neurons, to inhibit pancreatic exocrine secretion. To test this hypothesis, amylase and volume outputs in response to secretin (10-8 mol/L) and cholecystokinin octapeptide (CCK) (10-8 mol/L) were studied in the rat isolated, perfused, pancreas model. Somatostatin (10-7 mol/L) significantly inhibited amylase output by 48% compared with control ( 352 ± 57 v 676 ± 85 U 30 min, P < .05 by ANOVA). Blockade of axonal neuronal transmission by tetrodotoxin (10-7 mol/L) completely abolished the inhibitory effect of somatostatin ( 992 ± 53 U 30 min). Similar effects were seen on volume output. The inhibitory effect of somatostatin on amylase output was not affected by cholinergic receptor blockade with atropine ( 328 ± 65 U 30 min) or by sympathetic ganglionic blockade with hexamethonium ( 360 ± 68 U 30 min). This suggests that the intrinsic pancreatic neurons responsible for the inhibitory effect of somatostatin are peptidergic. The possibility that somatostatin acts directly on the acinar cell to inhibit exocrine secretion was tested by incubating varying doses of somatostatin (10-12 to 10-7 mol/L) with isolated pancreatic acini in the presence of graded concentrations of CCK (10-12 to 10-10 mol/L). In this model, CCK alone is a potent stimulant of amylase release, with a Km of 6 × 10-12 mol/L and a Vmax of 22 ± 3% total amylase. In this model, somatostatin had no inhibitory effect. The possibility that somatostatin releases a secondary inhibitory mediator from the pancreas was tested by perfusing rat pancreata arterially with 10-7 mol/L somatostatin and collecting portal venous effuent. Aliquots of unconcentrated and 60-fold concentrated portal venous effluent were tested for inhibitory activity in the isolated acinar preparation in the presence of graded concentrations of CCK. As control, portal venous effluent was collected from pancreata perfused arterially with buffer alone. No inhibitory activity was identified in these perfusated suggesting that somatostatin does not release a secondary inhibitory substance to modulate pancreatic inhibition. We conclude that the mechanism of inhibition of pancrestic exocrine secretion by somatostatin is indirect, via intrinsic, inhibitory pancreatic neurons. These neurons are likely peptidergic.
AB - The mechanism of inhibition of pancreatic exocrine secretion by somatostatin is unknown. We hypothesized that somatostatin acts indirectly, via intrinsic pancreatic neurons, to inhibit pancreatic exocrine secretion. To test this hypothesis, amylase and volume outputs in response to secretin (10-8 mol/L) and cholecystokinin octapeptide (CCK) (10-8 mol/L) were studied in the rat isolated, perfused, pancreas model. Somatostatin (10-7 mol/L) significantly inhibited amylase output by 48% compared with control ( 352 ± 57 v 676 ± 85 U 30 min, P < .05 by ANOVA). Blockade of axonal neuronal transmission by tetrodotoxin (10-7 mol/L) completely abolished the inhibitory effect of somatostatin ( 992 ± 53 U 30 min). Similar effects were seen on volume output. The inhibitory effect of somatostatin on amylase output was not affected by cholinergic receptor blockade with atropine ( 328 ± 65 U 30 min) or by sympathetic ganglionic blockade with hexamethonium ( 360 ± 68 U 30 min). This suggests that the intrinsic pancreatic neurons responsible for the inhibitory effect of somatostatin are peptidergic. The possibility that somatostatin acts directly on the acinar cell to inhibit exocrine secretion was tested by incubating varying doses of somatostatin (10-12 to 10-7 mol/L) with isolated pancreatic acini in the presence of graded concentrations of CCK (10-12 to 10-10 mol/L). In this model, CCK alone is a potent stimulant of amylase release, with a Km of 6 × 10-12 mol/L and a Vmax of 22 ± 3% total amylase. In this model, somatostatin had no inhibitory effect. The possibility that somatostatin releases a secondary inhibitory mediator from the pancreas was tested by perfusing rat pancreata arterially with 10-7 mol/L somatostatin and collecting portal venous effuent. Aliquots of unconcentrated and 60-fold concentrated portal venous effluent were tested for inhibitory activity in the isolated acinar preparation in the presence of graded concentrations of CCK. As control, portal venous effluent was collected from pancreata perfused arterially with buffer alone. No inhibitory activity was identified in these perfusated suggesting that somatostatin does not release a secondary inhibitory substance to modulate pancreatic inhibition. We conclude that the mechanism of inhibition of pancrestic exocrine secretion by somatostatin is indirect, via intrinsic, inhibitory pancreatic neurons. These neurons are likely peptidergic.
UR - http://www.scopus.com/inward/record.url?scp=0025125265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025125265&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(90)90233-3
DO - 10.1016/0026-0495(90)90233-3
M3 - Article
C2 - 1698248
AN - SCOPUS:0025125265
SN - 0026-0495
VL - 39
SP - 143
EP - 148
JO - Metabolism
JF - Metabolism
IS - 9 SUPPL. 2
ER -